| Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (NCT03810313) | Novartis Pharmaceuticals | 2019-07-03 |
| Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (NCT03802630) | Novartis Pharmaceuticals | 2019-07-02 |
| Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF) (NCT03988634) | Novartis Pharmaceuticals | 2019-06-29 |
| Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (NCT03960840) | Novartis Pharmaceuticals | 2019-06-26 |
| HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) (NCT03940352) | Novartis Pharmaceuticals | 2019-06-24 |
| Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (NCT03876769) | Novartis Pharmaceuticals | 2019-06-24 |
| Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients (NCT03876028) | Novartis Pharmaceuticals | 2019-06-11 |
| Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (NCT03822468) | Novartis Pharmaceuticals | 2019-06-11 |
| A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers (NCT04665154) | Novartis Pharmaceuticals | 2019-06-07 |
| Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD (NCT03954626) | Novartis Pharmaceuticals | 2019-06-07 |
| An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) (NCT03769168) | Novartis Pharmaceuticals | 2019-06-07 |
| This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines (NCT03926611) | Novartis Pharmaceuticals | 2019-06-06 |
| A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). (NCT03946670) | Novartis Pharmaceuticals | 2019-06-04 |
| AScalate: Treat-to-target in Axial Spondyloarthritis (NCT03906136) | Novartis Pharmaceuticals | 2019-06-04 |
| Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema (NCT03927690) | Novartis Pharmaceuticals | 2019-05-24 |
| Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration (NCT03930641) | Novartis Pharmaceuticals | 2019-05-23 |
| Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (NCT03798626) | Novartis Pharmaceuticals | 2019-05-22 |
| A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia (NCT03810183) | Novartis Pharmaceuticals | 2019-05-21 |
| Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (NCT03570892) | Novartis Pharmaceuticals | 2019-05-09 |
| Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (NCT03891953) | Novartis Pharmaceuticals | 2019-05-07 |
| An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan. (NCT03909295) | Novartis Pharmaceuticals | 2019-05-07 |
| Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF (NCT03785405) | Novartis Pharmaceuticals | 2019-05-02 |
| Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma (NCT03650400) | Novartis Pharmaceuticals | 2019-05-01 |
| A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia. (NCT03809611) | Novartis Pharmaceuticals | 2019-04-26 |
| COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure (NCT03917459) | Novartis Pharmaceuticals | 2019-04-16 |
| Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C (NCT03814187) | Novartis Pharmaceuticals | 2019-04-16 |
| A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines (NCT03907878) | Novartis Pharmaceuticals | 2019-04-13 |
| Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) (NCT03945318) | Novartis Pharmaceuticals | 2019-04-08 |
| Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT03896152) | Novartis Pharmaceuticals | 2019-04-05 |
| A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients (NCT03948334) | Novartis Pharmaceuticals | 2019-04-04 |
| Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma (NCT03681093) | Novartis Pharmaceuticals | 2019-03-26 |
| A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia (NCT03874858) | Novartis Pharmaceuticals | 2019-03-22 |
| A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML (NCT03591510) | Novartis Pharmaceuticals | 2019-03-13 |
| Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa (NCT03827798) | Novartis Pharmaceuticals | 2019-02-27 |
| Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) (NCT03713632) | Novartis Pharmaceuticals | 2019-02-25 |
| Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer (NCT03839823) | Novartis Pharmaceuticals | 2019-02-25 |
| Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine (NCT03828539) | Novartis Pharmaceuticals | 2019-02-22 |
| Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease (NCT03491215) | Novartis Pharmaceuticals | 2019-02-21 |
| Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted (NCT03832114) | Novartis Pharmaceuticals | 2019-02-20 |
| Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (NCT03610724) | Novartis Pharmaceuticals | 2019-02-15 |
| Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients (NCT03623243) | Novartis Pharmaceuticals | 2019-02-14 |
| Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression (NCT03756129) | Novartis Pharmaceuticals | 2019-02-08 |
| A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (NCT03851705) | Novartis Pharmaceuticals | 2019-02-06 |
| This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). (NCT03713619) | Novartis Pharmaceuticals | 2019-01-31 |
| Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). (NCT03742349) | Novartis Pharmaceuticals | 2019-01-31 |
| A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis (NCT03765788) | Novartis Pharmaceuticals | 2019-01-30 |
| Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (NCT03626545) | Novartis Pharmaceuticals | 2019-01-23 |
| Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab (NCT03553823) | Novartis Pharmaceuticals | 2019-01-14 |
| A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type. (NCT02989402) | Novartis Pharmaceuticals | 2018-12-31 |
| Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (NCT03650114) | Novartis Pharmaceuticals | 2018-12-28 |
| Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer (NCT03696771) | Novartis Pharmaceuticals | 2018-12-27 |
| Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer (NCT03647488) | Novartis Pharmaceuticals | 2018-12-26 |
| Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (NCT03631199) | Novartis Pharmaceuticals | 2018-12-21 |
| Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis (NCT03589885) | Novartis Pharmaceuticals | 2018-12-19 |
| Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients (NCT03656562) | Novartis Pharmaceuticals | 2018-12-19 |
| Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis (NCT03574545) | Novartis Pharmaceuticals | 2018-12-19 |
| Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy (NCT03804879) | Novartis Pharmaceuticals | 2018-12-17 |
| Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function (NCT03718533) | Novartis Pharmaceuticals | 2018-12-17 |
| Systemic Corticosteroids Avoidance Study in Severe Asthma Patients (NCT03629249) | Novartis Pharmaceuticals | 2018-12-13 |
| Study of Efficacy of PEAR-004 in Schizophrenia (NCT03751280) | Novartis Pharmaceuticals | 2018-12-10 |
| A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NCT03701334) | Novartis Pharmaceuticals | 2018-12-07 |
| Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (NCT03663335) | Novartis Pharmaceuticals | 2018-11-28 |
| Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) (NCT03887520) | Novartis Pharmaceuticals | 2018-11-27 |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. (NCT03578367) | Novartis Pharmaceuticals | 2018-11-22 |
| Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers (NCT03605277) | Novartis Pharmaceuticals | 2018-11-16 |
| A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis (NCT03517566) | Novartis Pharmaceuticals | 2018-11-14 |
| Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (NCT03568461) | Novartis Pharmaceuticals | 2018-11-12 |
| Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. (NCT03525834) | Novartis Pharmaceuticals | 2018-11-09 |
| A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP (NCT03524612) | Novartis Pharmaceuticals | 2018-11-02 |
| Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections (NCT03710564) | Novartis Pharmaceuticals | 2018-10-30 |
| A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection (NCT03369912) | Novartis Pharmaceuticals | 2018-10-23 |
| A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. (NCT03580356) | Novartis Pharmaceuticals | 2018-10-20 |
| LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI) (NCT03377426) | Novartis Pharmaceuticals | 2018-10-19 |
| A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines (NCT03580369) | Novartis Pharmaceuticals | 2018-10-17 |
| Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation (NCT03398434) | Novartis Pharmaceuticals | 2018-10-16 |
| Determine the Safety, Tolerability, and Efficacy of MAU868 for the Prevention of BK Virus Infection in Kidney Transplant Recipients (NCT03456999) | Novartis Pharmaceuticals | 2018-10-15 |
| Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients (NCT03630159) | Novartis Pharmaceuticals | 2018-10-09 |
| Prevention of Thromboembolic Events in Total Knee Replacement Patients (NCT03393481) | Novartis Pharmaceuticals | 2018-10-03 |
| Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients (NCT03474965) | Novartis Pharmaceuticals | 2018-10-01 |
| Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA) (NCT04174157) | Novartis Pharmaceuticals | 2018-09-25 |
| Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects (NCT03681457) | Novartis Pharmaceuticals | 2018-09-24 |
| Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis. (NCT03610516) | Novartis Pharmaceuticals | 2018-09-12 |
| A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients (NCT03560739) | Novartis Pharmaceuticals | 2018-09-11 |
| Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis (NCT03517540) | Novartis Pharmaceuticals | 2018-09-11 |
| Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne (NCT03497897) | Novartis Pharmaceuticals | 2018-09-10 |
| Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (NCT03484923) | Novartis Pharmaceuticals | 2018-09-10 |
| Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC (NCT02672358) | Novartis Pharmaceuticals | 2018-09-03 |
| Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (NCT03671330) | Novartis Pharmaceuticals | 2018-08-29 |
| Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (NCT03551626) | Novartis Pharmaceuticals | 2018-08-29 |
| Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis (NCT03668613) | Novartis Pharmaceuticals | 2018-08-29 |
| A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa (NCT03374657) | Novartis Pharmaceuticals | 2018-08-22 |
| Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU) (NCT03437278) | Novartis Pharmaceuticals | 2018-08-01 |
| Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) (NCT03240393) | Novartis Pharmaceuticals | 2018-07-31 |
| A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (NCT03481660) | Novartis Pharmaceuticals | 2018-07-27 |
| Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations (NCT03529084) | Novartis Pharmaceuticals | 2018-07-24 |
| Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (NCT03481634) | Novartis Pharmaceuticals | 2018-07-23 |
| A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) (NCT03512197) | Novartis Pharmaceuticals | 2018-07-20 |
| A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NCT03549000) | Novartis Pharmaceuticals | 2018-07-18 |
| A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence (NCT03379233) | Novartis Pharmaceuticals | 2018-07-11 |
| The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients (NCT03300427) | Novartis Pharmaceuticals | 2018-07-05 |